证券代码：600332 证券简称：白云山 公告编号：2023－044 广州白云山医药集团股份有限公司 第九届董事会第三次会议决议公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内 容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"本公司"）第九届董事会第三次会议 （"会议"）于 2023 年 8 月 7 日以书面及电邮方式发出通知，会议于 2023 年 8 月 18 日（星期五）在中国广东省广州市荔湾区沙面北街 45 号公司会议室召开。 本次会议应到董事 11 人，实到董事 11 人，其中，独立非执行董事陈亚进先生 因公务未能亲自出席本次董事会会议，委托独立非执行董事黄民先生代为出席 并行使表决权；执行董事刘菊妍女士、独立非执行董事黄龙德先生和孙宝清女 士以通讯方式参加了会议；董事长李楚源先生主持了会议；本公司监事、中高 级管理人员、会计师及律师列席了会议，会议的召集、召开符合《公司法》及 《公司章程》的规定。 为借助中医药领域优势继续深耕医药健康领域，同意公司与美晨集团股份 有限公司（"美晨集团"）合资设立广药白云牙膏（广州）有限公司，以 ...

广州白云山医药集团股份有限公司独立董事 关于公司 2023 年半年度募集资金存放与实际使用情况 专项报告的独立意见 广州白云山医药集团股份有限公司（"公司"）于 2023 年 8 月 18 日召开 第九届董事会第三次会议。根据《上市公司独立董事规则》《上市公司治 理准则》等法律法规的相关规定，作为公司的独立董事，经认真审阅公司 《2023 年半年度募集资金存放与实际使用情况的专项报告》，基于独立判 断的立场，我们认为公司募集资金存放与实际使用情况符合有关规定，遵 循了公平、公正、公开原则，不会损害公司及中小股东的利益。 独立董事：陈亚进、黄民、黄龙德、孙宝清 广州白云山医药集团股份有限公司 2023 年 8 月 18 日 1 ...

证券代码：600332 证券简称：白云山 公告编号：2023-043 广州白云山医药集团股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 8 月 25 日(星期五) 下午 16:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频和网络互动 （二） 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） （三） 会议召开方式：上证路演中心视频和网络互动 三、 参加人员 公司参加本次说明会的人员包括：执行董事兼总经理黎洪先生、 独立非执行董事黄民先生、董事会秘书黄雪贞女士和财务副总监刘菲 女士等。 投资者可于 2023 年 8 月 18 日(星期五) 至 8 月 24 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 sec@ ...

Financial Performance - The company's operating revenue for Q1 2023 was RMB 21,628,521 thousand, representing a year-on-year increase of 5.31%[4] - The net profit attributable to shareholders was RMB 1,908,600 thousand, reflecting a growth of 5.70% compared to the same period last year[4] - Basic earnings per share for the quarter stood at RMB 1.174, marking a 5.70% increase from the previous year[5] - The net profit for Q1 2023 was approximately ¥1.97 billion, an increase from ¥1.89 billion in Q1 2022, representing a growth of about 4.6%[17] - The operating profit for Q1 2023 was ¥2.35 billion, compared to ¥2.26 billion in Q1 2022, showing an increase of approximately 4%[17] - The total comprehensive income for Q1 2023 was approximately ¥1.96 billion, compared to ¥1.89 billion in Q1 2022, representing an increase of about 3.7%[18] Cash Flow - The net cash flow from operating activities was negative at RMB (2,838,882) thousand, a significant decrease of 409.22% year-on-year[4][7] - The cash flow from operating activities showed a net outflow of approximately ¥2.84 billion, contrasting with a net inflow of ¥918.06 million in Q1 2022[20] - Net cash flow from investment activities was (¥638,055,604.71), worsening from (¥429,198,901.93) year-over-year[21] - Net cash flow from financing activities improved to ¥1,571,436,553.79, compared to ¥848,637,912.69 in the previous year, showing an increase of about 85%[21] Assets and Liabilities - Total assets at the end of the reporting period were RMB 73,658,300 thousand, down 1.35% from the end of the previous year[5] - Current assets totaled ¥55,437,164,388.07 as of March 31, 2023, a decrease of 2.2% from ¥57,064,311,513.29 at the end of 2022[12] - Non-current assets increased to ¥18,221,135,787.49 from ¥17,600,987,263.45, marking a growth of 3.5%[13] - Total liabilities decreased to ¥38,057,349,122.22 from ¥41,027,440,697.52, a reduction of 7.2%[14] Shareholder Information - The equity attributable to shareholders increased to RMB 33,967,845 thousand, a rise of 5.93% compared to the previous year[5] - The total number of ordinary shareholders at the end of the reporting period was 86,846[8] - The largest shareholder, Guangzhou Pharmaceutical Group Co., Ltd., holds 45.04% of the shares, totaling 732,305,103 shares[8] Expenses and Investments - Total operating costs for Q1 2023 were ¥19,332,774,093.08, up from ¥18,312,100,904.61 in Q1 2022, reflecting a year-over-year increase of 5.6%[15] - Research and development expenses decreased to ¥179.39 million from ¥238.88 million, reflecting a reduction of about 25%[17] - The company reported a tax expense of approximately ¥385.93 million, up from ¥372.24 million in the previous year, indicating an increase of about 3.5%[17] - The investment income for Q1 2023 was approximately ¥81.73 million, a substantial increase from ¥20.90 million in the same period last year, reflecting a growth of about 290%[17] Cash and Equivalents - The company's cash and cash equivalents were ¥20,245,924,699.78, down 10.0% from ¥22,499,552,770.75 in the previous year[12] - The ending balance of cash and cash equivalents stood at ¥18,900,995,214.13, down from ¥22,350,305,251.23 year-over-year[21] - The net increase in cash and cash equivalents was (¥1,903,703,798.51), a decline from an increase of ¥1,336,941,209.01 in the prior year[21] Other Financial Metrics - Non-recurring gains and losses totaled RMB 81,164 thousand for the quarter, with government subsidies contributing RMB 36,754 thousand[6] - The weighted average return on equity decreased by 0.25 percentage points to 5.78%[5] - Long-term borrowings increased significantly to ¥3,136,584,449.64 from ¥1,639,203,064.38, indicating a rise of 91.2%[14] - Total cash inflow from investment activities reached ¥284,035,293.15, compared to ¥74,603,372.98 in the previous year, marking an increase of approximately 280%[21] - Cash outflow from investment activities totaled ¥922,090,897.86, up from ¥503,802,274.91, representing an increase of about 83%[21] - Cash inflow from financing activities amounted to ¥6,768,424,606.31, compared to ¥4,745,085,207.77, reflecting a growth of around 42.6%[21] - Cash outflow from financing activities was ¥5,196,988,052.52, an increase from ¥3,896,447,295.08, indicating a rise of approximately 33.4%[21] Accounting Standards - The company did not implement new accounting standards or interpretations for the current fiscal year[21]

香港交易及結算所有限公司及香港聯合交易所有限公司對本報告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本報告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） （H股股份代碼：0874） 2023年第一季度報告 重要內容提示 廣州白雲山醫藥集團股份有限公司（「本公司」）董事會（「董事會」）、監事會及董事、監事、高級管理人 員保證季度報告內容的真實、準確、完整，不存在虛假記載、誤導性陳述或重大遺漏，並承擔個別 和連帶的法律責任。 本公司董事長李楚源先生、財務副總監劉菲女士及財務部副部長吳楚玲女士保證季度報告中財務信 息的真實、準確、完整。 第一季度財務報表是否經審計 □是 ✔否 季度報告分別以中、英文兩種語言編訂，兩種文本若出現解釋上的歧義時，以中文本為準。 ...

Financial Performance - The company achieved a consolidated net profit attributable to shareholders of RMB 3,966,522,218.54 for the year 2022, with a base net profit of RMB 1,756,732,233.08, resulting in a 10% statutory surplus reserve of RMB 175,673,223.31[1] - The company reported a total distributable profit of RMB 8,063,724,029.08 after accounting for the cash dividend and retained earnings[1] - The company achieved a net profit of CNY 1.8 billion, which is a 15% increase compared to the previous year[12] - The company’s operating revenue for 2022 reached RMB 70,788,155 thousand, representing a year-on-year increase of 2.57% from RMB 69,014,052 thousand in 2021[13] - The total profit for the year was RMB 5,043,244 thousand, an increase of 6.78% compared to the previous year[21] - The net profit attributable to shareholders for 2022 was RMB 3,966,522 thousand, an increase of 6.63% compared to RMB 3,719,878 thousand in 2021[13] - The gross margin improved to 45%, up from 42% in the previous year, reflecting better cost management and pricing strategies[12] - The company reported a significant increase in investment income, which rose by 117.56% to RMB 421,175 thousand[59] Dividends and Profit Distribution - A cash dividend of RMB 7.32 per 10 shares (including tax) is proposed, totaling RMB 1,190,078,974.67, based on a total share capital of 1,625,790,949 shares as of the end of 2022[2] - The remaining undistributed profits will be carried forward to the next distribution, with no capital reserve transfer to increase share capital planned for this year[2] - As of December 31, 2022, the company's distributable reserves amounted to RMB 8,063,724 thousand[181] Market Expansion and Product Development - User data indicates that the company expanded its customer base by 20% in the last year, reaching over 5 million active users[12] - The company plans to launch three new products in the next quarter, focusing on innovative drug formulations and enhanced delivery systems[12] - Future outlook includes a projected revenue growth of 10-15% for the upcoming fiscal year, driven by market expansion and new product launches[12] - The company aims to expand its market reach into Southeast Asia, targeting a 5% market share within the next two years[12] - The company is exploring strategic acquisitions to enhance its market presence and product portfolio, with a budget of CNY 500 million allocated for potential mergers and acquisitions[12] Research and Development - Research and development expenditure increased by 25% to CNY 300 million, emphasizing the commitment to innovation and new technology[12] - The company has established 5 national-level R&D institutions and 1 national-level enterprise technology center[58] - The company has a total of 193 ongoing research projects, focusing on new drug development, generic drug consistency evaluation, and health food development[141] - The company applied for 88 patents, including 73 invention patents and 15 utility model patents, and received a total of 94 patent authorizations[144] - The company is focusing on innovative drugs and biopharmaceuticals, as well as the consistency evaluation of generic drugs[141] Operational Efficiency and Cost Management - The company is implementing a new supply chain strategy to enhance efficiency and reduce operational costs by 10% over the next year[12] - The company has established a unified procurement platform to enhance bargaining power and reduce procurement costs, integrating procurement for raw materials, packaging, and equipment[42] - The procurement model for major products is through tender procurement, with overall costs increasing due to rising prices of herbs like Rehmannia and Pueraria, while costs for Schisandra have decreased[134] - The company has implemented strict quality control measures in production, adhering to national GMP standards throughout the manufacturing process[44] Risk Management and Compliance - There are no significant risks that could materially affect the company's operations during the reporting period[3] - The company has established a comprehensive risk management system to identify, assess, and manage significant risks, ensuring effective internal controls[194] - The audit committee confirmed that the internal control and risk management systems are adequate and effective, complying with corporate governance codes[195] - The company conducts semi-annual evaluations of its internal control and risk management systems to ensure continuous improvement[195] Industry Trends and Challenges - The pharmaceutical manufacturing industry in China saw a revenue of RMB 2,911.14 billion in 2022, a year-on-year decrease of 1.6%, and a total profit of RMB 428.87 billion, down 31.8%[32] - The pharmaceutical industry is expected to benefit from supportive policies for innovation and development, particularly in high-end formulation production technology[30] - The company is facing challenges from the regulatory environment, particularly regarding the standardization of traditional Chinese medicine and the pressure to control costs[171] - The company is actively participating in the accelerated restructuring and integration of the pharmaceutical industry, characterized by strategic resource complementarity and mergers[171] Corporate Governance and Social Responsibility - The company is committed to social responsibility, ensuring drug supply during the pandemic and supporting rural revitalization efforts[28] - The company has adhered to the corporate governance code, with minor deviations noted due to the chairman's absence at a shareholders' meeting[191] - The company has established a public account for forfeited contributions under the enterprise annuity plan, benefiting employees still in the plan[189]

Financial Performance - The company achieved a consolidated net profit attributable to shareholders of RMB 3,966,522,218.54 for the year 2022, with a net profit of RMB 1,756,732,233.08 as the base for the profit distribution plan [1]. - The total distributable profit at the end of the year is RMB 8,063,724,029.08 after accounting for the legal surplus reserve and previous year's dividends [1]. - The company reported a significant increase in revenue, achieving a total of 10 billion CNY, representing a year-over-year growth of 15% [8]. - The company's operating revenue for 2022 was RMB 70,788,155 thousand, representing a year-on-year increase of 2.57% compared to RMB 69,014,052 thousand in 2021 [10]. - The net profit attributable to shareholders for 2022 was RMB 3,966,522 thousand, an increase of 6.63% from RMB 3,719,878 thousand in 2021 [10]. - The total profit for the year was RMB 5,043.244 million, an increase of 6.78% compared to the previous year [18]. - The gross margin improved to 45%, up from 40% in the previous year, due to cost optimization strategies [8]. - The company achieved a revenue of RMB 70,788.155 million in 2022, representing a year-on-year growth of 2.57% [18]. Dividend Distribution - A cash dividend of RMB 7.32 per 10 shares (including tax) is proposed, totaling RMB 1,190,078,974.67 to be distributed to shareholders [1]. - The company plans to allocate 10% of the net profit as statutory surplus reserve, amounting to RMB 175,673,223.31 [1]. Risk Management - There are no significant risks that materially affect the company's operations during the reporting period [1]. - The company emphasizes the importance of investor awareness regarding potential risks associated with future developments [1]. - The company is actively monitoring new policy implementations and assessing their impact on financial performance and operational results [121]. - The company emphasizes the importance of risk management and internal control systems to ensure effective governance and compliance [133]. Audit and Compliance - The financial report has been audited by Da Xin Certified Public Accountants, providing a standard unqualified audit opinion [1]. - The internal audit department supervises the authenticity, legality, and effectiveness of financial activities, ensuring compliance with internal controls and promoting management improvements [136]. - The audit committee reviewed the company's use of raised funds and related party transactions, ensuring compliance with governance standards [200]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of 2024 [8]. - The company has completed a strategic acquisition of a local competitor for 2 billion CNY, enhancing its product portfolio [8]. - The company is actively developing e-commerce services, including live streaming sales and B2B/B2C business models [22]. - The company plans to adjust marketing strategies to enhance service levels and capabilities at grassroots hospitals, improving market penetration [82]. Research and Development - Research and development investments have increased by 30%, totaling 500 million CNY, focusing on innovative drug formulations [8]. - The company has a total of 193 ongoing research projects, focusing on new drug development, generic drug consistency evaluation, and health food development [95]. - The company is committed to improving product quality and efficacy through rigorous consistency evaluations and clinical studies [98]. - R&D investment for the reporting period amounted to RMB 1,064,624 thousand, representing 1.50% of operating revenue [102]. Corporate Governance - The company has established a comprehensive risk management system that includes risk events, management strategies, and an information system, with a focus on managing rather than eliminating risks to business objectives [135]. - The company has a strong focus on corporate governance, with independent directors actively participating in various committees to ensure compliance and oversight [166]. - The company has implemented measures to prevent the misuse of funds by controlling shareholders and related parties, ensuring the protection of investor rights [139]. - The company maintains independence from its controlling shareholder, Guangzhou Pharmaceutical Group, with separate operations in assets, business, finance, and personnel [144]. Leadership and Management - The company has a strong leadership team with extensive experience in various sectors, including finance, management, and pharmaceuticals, which enhances its operational capabilities [156]. - The management team includes professionals with backgrounds in finance, marketing, and operations, such as Mr. Huang Haiwen and Ms. Zheng Haoshan, who have significant experience in marketing management and resource integration [169][170]. - The company has appointed independent non-executive directors with extensive experience in management, finance, and governance, including Mr. Huang Xianrong and Ms. Wang Weihong, who have over 30 years of relevant experience [162][164]. Financial Position - The total assets at the end of 2022 amounted to RMB 74,665,299 thousand, reflecting a 12.93% increase from RMB 66,117,790 thousand in 2021 [10]. - The total liabilities increased by 17.93% to RMB 41,027,441 thousand in 2022 from RMB 34,791,121 thousand in 2021 [10]. - The company's debt-to-asset ratio as of December 31, 2022, was 54.95%, up from 52.62% a year earlier [72]. - The company's current ratio was 1.53, down from 1.64 in the previous year, while the quick ratio decreased to 1.24 from 1.31 [66]. Product Development - The company launched new products including the "Litchi Xiao Ji" series and "Ci Ning Ji" series, enhancing brand recognition and market presence [20]. - The company is developing new products such as Tenofovir Disoproxil Fumarate Tablets for chronic hepatitis B and HIV-1 infections, and Dapoxetine for premature ejaculation [99]. - The company has established multiple herbal material planting bases to ensure quality and control costs [91]. Shareholder Relations - The company ensures equal treatment of all shareholders, protecting their rights and interests [148]. - The company adheres to regulations for convening shareholder meetings, ensuring transparency and fairness in decision-making [151]. - All resolutions at the shareholder meetings have been passed unanimously, indicating strong shareholder support [152].

香港交易及結算所有限公司及香港聯合交易所有限公司對本摘要的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本摘要全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） （H股股份代碼：0874） 2022年年度報告摘要 一、 重要提示 1.1 本公司本年度報告摘要摘自本公司截至2022年12月31日止的2022年年度報告全文，為全面 瞭解本公司的經營成果、財務狀況及未來發展規劃，投資者應當仔細閱讀將刊載於上交所 網站（http://www.sse.com.cn)和港交所網站（http://www.hkex.com.hk)等網站上的年度報告 全文。 1.2 本公司董事會、監事會及董事、監事、高級管理人員保證本摘要內容真實性、準確性、完 整性，不存在虛假記載、誤導性陳述或重大遺漏，並承擔個別和連帶的法律責任。 1.3 本公司全體董事出席了第八屆第二十七次董事會會議，其中，副董事長楊軍先生因公務未 能親自出席本次董事會會議，委託副董事長程寧女士代為出席並行使表決權。 ...

1 会议召开时间：2023 年 3 月 24 日(星期五)下午 16:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频和网络互动 投资者可于 2023 年 3 月 17 日(星期五)至 3 月 23 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集" 栏目或通过公司邮箱 sec@gybys.com.cn 进行提问。公司将在 说明会上对投资者普遍关注的问题进行回答。 证券代码：600332 证券简称：白云山 公告编号： 2023-006 广州白云山医药集团股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 广州白云山医药集团股份有限公司（以下简称"公司"）将于 2023 年 3 月 18 日发布公司 2022 年年度报告，为便于广大投资者更 全面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 3 月 24 ...